Muscle News and Research

RSS

UC San Diego Sulpizio listed in “100 Hospitals with Great Heart Programs”

UC San Diego Sulpizio Cardiovascular Center (SCVC) has been featured in the latest Becker's Hospital Review list of "100 Hospitals with Great Heart Programs."

20 Dec 2013

New antibody could boost strength, muscle mass in patients with cancer and other diseases

A new antibody could dramatically boost strength and muscle mass in patients with cancer, chronic obstructive pulmonary disease, sporadic inclusion body myositis, and in elderly patients with sarcopenia according to research published ahead of print in the journal Molecular and Cellular Biology.

20 Dec 2013

UC Irvine scientists find that reprogramming of liver 'clock' may contribute to metabolic disorders

A high-fat diet affects the molecular mechanism controlling the internal body clock that regulates metabolic functions in the liver, UC Irvine scientists have found. Disruption of these circadian rhythms may contribute to metabolic distress ailments, such as diabetes, obesity and high blood pressure.

20 Dec 2013

Osteoarthritis patients can carry out progressive exercise to maintain bone health

The postmenopausal women who may be at risk of osteoporosis (bone loss), as well as at risk of osteoarthritis, can safely carry out progressive high-impact training to maintain bone health and physical function.

19 Dec 2013

Endocrine Society issues scientific statement on health consequences of performance-enhancing drugs

A new Scientific Statement issued today by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs. The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem.

18 Dec 2013

New gene mutation helps doctors give more accurate diagnosis of mitochondrial myopathy

A new gene mutation which will help doctors give a more accurate diagnosis of a particular type of brain and muscle disease in children has been discovered for the first time by University of Leeds experts.

17 Dec 2013

Study provides important new perspective on how we look at bladder cancer biology

Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isn't fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive bladder cancer eventually become the more dangerous, muscle-invasive form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?

17 Dec 2013

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Ipsen today announced positive initial results from the double-blind phase III study of Dysport (abobotulinumtoxinA) in Adult Upper Limb spasticity. Regarding the primary endpoints, treatment with Dysport showed statistically significant response versus placebo in the improvement of muscle tone, as measured by the Modified Ashworth Scale.

17 Dec 2013

Norgine signs exclusive licensing agreement with Innovacell for ICEF15

Norgine B.V. and Innovacell today announced they have entered into an exclusive licensing agreement for Europe, SADAC and MENA for ICEF15. Innovacell and Norgine will co-develop ICEF15 and Norgine will commercialise the product. The start of the ICEF15 phase IIb clinical trial is imminent and it is anticipated that the first patient will be dosed in Q1 2014.

17 Dec 2013

Research findings point to possible new strategy for treating ALS

Amyotrophic lateral sclerosis, better known as Lou Gehrig's disease, is a devastating illness that gradually robs sufferers of muscle strength and eventually causes a lethal, full-body paralysis. The only drug available to treat the disease extends life spans by a meager three months on average.

17 Dec 2013

Incision technique shows potential for bladder neck contracture

A US team reports that deep lateral transurethral incisions are a promising technique for the treatment of recurrent bladder neck contracture in men following prostate surgery.

16 Dec 2013

Research roundup: Long-term care use varies dramatically by state; health spending slowdown explained

In 2012, about 58,500 paid, regulated long-term care services providers served about 8 million people in the United States. Long-term care services were provided by 4,800 adult day services centers, 12,200 home health agencies, 3,700 hospices, 15,700 nursing homes, and 22,200 assisted living and similar residential care communities. Each day in 2012, there were 273,200 participants enrolled in adult day services centers, 1,383,700 residents in nursing homes, and 713,300 residents in residential care communities; in 2011, about 4,742,500 patients received services from home health agencies, and 1,244,500 patients received services from hospices. Provider sectors differed in ownership, and average size and supply varied by region (Harris-Kojetin et al., 12/12).

16 Dec 2013

IOF Young Investigator Awards presented to five researchers at 4th Asia-Pacific Osteoporosis Meeting

Today, the International Osteoporosis Foundation recognized the outstanding work of five young researchers from China, Chinese Taipei, Hong Kong, Malaysia and Pakistan.

16 Dec 2013

Exercise in middle age protects against sarcopenia and maintains muscle strength, physical performance

A cross-sectional study by investigators from Tokyo University has found that exercising in middle age is a protective factor against sarcopenia and effective in maintaining muscle strength and physical performance.

16 Dec 2013

Researchers identify new method to predict outcomes in heart failure patients

Researchers at the George Washington University School of Medicine and Health Sciences (SMHS) and Johns Hopkins University School of Medicine have identified a new method to determine whether a patient's heart will fail, which in the future may help physicians better treat patients and tailor therapeutic interventions.

16 Dec 2013

$Early initiation of treatment after primary hip fracture helps reduce second fracture incidence, mortality$

Early initiation of treatment after primary hip fracture helps reduce second fracture incidence, mortality

Research presented today at the 4th Asia-Pacific Osteoporosis Meeting showed that second hip fractures are more deadly than first hip fractures. Based in Hong Kong, the study evaluated the overall incidence of a second hip fracture and subsequent mortality in 43,832 patients, aged 65 or above, with operatively treated first hip fracture during the years 2000-2011.

15 Dec 2013

UTHealth Medical School professor recognized for excellence in sarcoma treatment

Rex Marco, M.D., professor in the Department of Orthopaedic Surgery at The University of Texas Health Science Center at Houston Medical School, is the recipient of an award recognizing excellence in the treatment of a type of cancer called sarcoma.

14 Dec 2013

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved the single tablet HIV-1 regimen Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable antiretroviral regimen in order to replace their current antiretroviral treatment regimen. Complera was first approved in 2011 for patients new to therapy and is now one of the most widely-prescribed HIV regimens in the United States.

13 Dec 2013

Spaceflights cause cellular-level damage and may lead to long-term vision problems

Those who travel to space are rewarded with a beautiful sight - planet Earth. But the effects of space travel on the human sense of sight aren't so beautiful. More than 30 percent of astronauts who returned from two-week space shuttle missions and 60 percent who spent six months aboard the International Space Station were diagnosed with eye problems. Two recent investigations examined mechanisms that may explain eye changes in spaceflight, help find ways to minimize this health risk to astronauts and eventually prevent and treat eye diseases on Earth.

13 Dec 2013

Muscle News and Research

UC San Diego Sulpizio listed in “100 Hospitals with Great Heart Programs”

New antibody could boost strength, muscle mass in patients with cancer and other diseases

UC Irvine scientists find that reprogramming of liver 'clock' may contribute to metabolic disorders

Osteoarthritis patients can carry out progressive exercise to maintain bone health

Endocrine Society issues scientific statement on health consequences of performance-enhancing drugs

New gene mutation helps doctors give more accurate diagnosis of mitochondrial myopathy

Study provides important new perspective on how we look at bladder cancer biology

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Ipsen reports positive initial results from Dysport phase III study in Adult Upper Limb spasticity

Norgine signs exclusive licensing agreement with Innovacell for ICEF15

Research findings point to possible new strategy for treating ALS

Incision technique shows potential for bladder neck contracture

Research roundup: Long-term care use varies dramatically by state; health spending slowdown explained

IOF Young Investigator Awards presented to five researchers at 4th Asia-Pacific Osteoporosis Meeting

Exercise in middle age protects against sarcopenia and maintains muscle strength, physical performance

Researchers identify new method to predict outcomes in heart failure patients

Early initiation of treatment after primary hip fracture helps reduce second fracture incidence, mortality

UTHealth Medical School professor recognized for excellence in sarcoma treatment

Gilead Sciences gets FDA approval for once-daily single tablet HIV-1 regimen Complera

Spaceflights cause cellular-level damage and may lead to long-term vision problems

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News